Myriad Genetics Corp - MYGN Net earnings per share (EPS TTM)

Geopolitical strife and reagent shortages have created challenges for global research, which is reflected in the price action. The rolling annual EPS change reached a peak, after which the metric level stood at 68.80. Meanwhile, Myriad Genetics, Inc. (MYGN) relies on a unique genomic dataset that creates a significant barrier to entry for competitors. High physician trust confirms its status as an authoritative leader in molecular diagnostics.
myriad.com - analytical breakdowns and key metrics (MYGN)

Cost optimization through the delegation of laboratory processes and biomaterial logistics allows Myriad Genetics, Inc. (MYGN) to flexibly manage margins. By analyzing the 12-month rolling EPS growth trend, an investor can track the percentage change in net income per share on a rolling basis, enabling a real-time assessment of the business model's efficiency and the timely identification of shifts in the company's fundamental earnings cycle.